

Ampio Pharmaceuticals, Inc.  
Form 10-Q  
August 16, 2010  
Table of Contents

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 10-Q**

x **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the Quarterly Period Ended: June 30, 2010**

or

.. **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from                      to**

**Commission File No. 333-146542**

**AMPIO PHARMACEUTICALS, INC.**

**(Exact name of registrant as specified in its charter)**

Edgar Filing: Ampio Pharmaceuticals, Inc. - Form 10-Q

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**26-0179592**  
(IRS Employee  
Identification No.)

**8400 East Crescent Parkway**

**Suite 600**

**Greenwood Village, Colorado 80111**

(Address of principal executive offices, including zip code)

**(303) 418-1000**

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of "accelerated filer", "large accelerated filer" and "smaller reporting company" in Rule 12B-2 of the Exchange Act. (Check one):

Large accelerated filer  Accelerated filer   
Non-accelerated filer  Smaller Reporting Company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

As of August 12, 2010, there were 17,060,036 shares outstanding of Common Stock, par value \$0.0001, of the registrant.

**Table of Contents**

**AMPIO PHARMACEUTICALS, INC.**

**AND SUBSIDIARIES**

**THREE AND SIX MONTHS ENDED JUNE 30, 2010**

**INDEX**

|  | <b>Page</b> |
|--|-------------|
| <b><u>PART I - FINANCIAL INFORMATION</u></b>   |             |
| Item 1. <u>Consolidated Financial Statements</u>   | 4           |
| <u>Consolidated Balance Sheets as of June 30, 2010 (unaudited) and December 31, 2009</u>   | 5           |
| <u>Consolidated Statements of Operations for the three and six months ended June 30, 2010 (unaudited), the three and six months ended June 30, 2009 (unaudited), and the period from December 31, 2008 (inception) through June 30, 2010</u> | 6           |
| <u>Consolidated Statement of Stockholders' Equity (Deficit)</u>  | 7           |
| <u>Consolidated Statements of Cash Flows for the six months ended June 30, 2010 (unaudited), the six months ended June 20, 2009 (unaudited), and the period from December 31, 2008 (inception) through June 30, 2010</u>                     | 8           |
| <u>Notes to Consolidated Financial Statements (unaudited)</u>  | 9           |
| Item 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>   | 12          |
| Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u>  | 15          |
| Item 4T. <u>Controls and Procedures</u>  | 15          |
| <b><u>PART II - OTHER INFORMATION</u></b>  |             |
| Item 1. <u>Legal Proceedings</u>   | 16          |
| Item 1A. <u>Risk Factors</u>   | 16          |
| Item 2. <u>Unregistered Sales of Equity Securities and Use of Proceeds</u>   | 16          |
| Item 3. <u>Defaults Upon Senior Securities</u>   | 16          |
| Item 4. <u>Removed and Reserved</u>  | 16          |
| Item 5. <u>Other Information</u>   | 16          |
| Item 6. <u>Exhibits</u>  | 16          |
| <b><u>SIGNATURES</u></b>   | 17          |

**Table of Contents**

**CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS**

*This Quarterly Report on Form 10-Q contains statements reflecting assumptions, expectations, projections, intentions or beliefs about future events that are intended as forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements included or incorporated by reference in this report, other than statements of historical fact, that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements appear in a number of places, including Management's Discussion and Analysis of Financial Condition and Results of Operations. These statements represent our reasonable judgment of the future based on various factors and using numerous assumptions and are subject to known and unknown risks, uncertainties and other factors that could cause our actual results and financial position to differ materially from those contemplated by the statements. You can identify these statements by the fact that they do not relate strictly to historical or current facts, and use words such as anticipate, believe, estimate, expect, forecast, may, should, plan, project and other words of similar meaning. In particular, these include, but are not limited to, statements relating to the following:*

*projected operating or financial results, including anticipated cash flows used in operations;*

*expectations regarding capital expenditures, research and development expense and other payments;*

*our beliefs and assumptions relating to our liquidity position, including our ability to obtain additional financing;*

*our ability to obtain regulatory approvals for our pharmaceutical drugs and diagnostics; and*

*our future dependence on third party manufacturers or strategic partners to manufacture any of our pharmaceutical drugs and diagnostics that receive regulatory approval.*

*Any or all of our forward-looking statements may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks, uncertainties and other factors including, among others:*

*the loss of key management personnel or sponsored research partners on whom we depend;*

*the progress and results of clinical trials for our product candidates;*

*our ability to navigate the regulatory approval process in the U.S. and other countries, and our success in obtaining required regulatory approvals for our product candidates;*

*commercial developments for products that compete with our product candidates;*

*the actual and perceived effectiveness of our product candidates, and how those product candidates compare to competitive products;*

*the strength of our intellectual property protection, and our success in avoiding infringing the intellectual property rights of others;*

## Edgar Filing: Ampio Pharmaceuticals, Inc. - Form 10-Q

*adverse developments in our research and development activities;*

*potential liability if our product candidates cause illness, injury or death, or adverse publicity from any such events;*

*our ability to operate our business efficiently, manage capital expenditures and costs (including general and administrative expenses) and obtain financing when required;*

*our expectations with respect to our acquisition activity.*

*In addition, there may be other factors that could cause our actual results to be materially different from the results referenced in the forward-looking statements, some of which are included elsewhere in this report, including Management's Discussion and Analysis of Financial Condition and Results of Operations. Many of these factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed. Our actual future results may vary materially from those expressed or implied in any forward-looking statements. All forward-looking statements contained in this report are qualified in their entirety by this cautionary statement. Forward-looking statements speak only as of the date they are made, and we disclaim any obligation to update any forward-looking statements to reflect events or circumstances after the date of this report, except as otherwise required by applicable law.*

**Table of Contents**

**PART I FINANCIAL INFORMATION**

**Item 1. Financial Statements**

*Note: The Consolidated Statement of Stockholders Equity (Deficit) is presented as additional investor information, as this Statement is not required by Form 10-Q.*

**Table of Contents****AMPIO PHARMACEUTICALS, INC. AND SUBSIDIARIES****(A Development Stage Company)****Consolidated Balance Sheets**

|   | <b>June 30,<br/>2010<br/>(unaudited)</b> | <b>December 31,<br/>2009</b> |
|---|--|------------------------------|
| <b>Assets</b>   |  |                              |
| Current assets  |  |                              |
| Cash and cash equivalents   | \$ 131,035                               | \$ 71,983                    |
| Restricted cash   | 105,000                                  |                              |
| Prepaid expenses  | 49,523                                   | 7,036                        |
| Related party receivable  | 7,238                                    | 7,261                        |
| Total current assets  | 292,796                                  | 86,280                       |
| Fixed assets  | 2,423                                    |                              |
| Total assets  | \$ 295,219                               | \$ 86,280                    |
| <b>Liabilities and Stockholders' Equity (Deficit)</b>   |  |                              |
| Accounts payable  | \$ 357,234                               | \$ 79,445                    |
| Accrued salaries  | 196,353                                  | 73,391                       |
| Accrued interest  | 7,595                                    | 1,414                        |
| Related party notes payable   | 400,000                                  | 200,000                      |
| Total current liabilities   | 961,182                                  | 354,250                      |
| Total liabilities   | 961,182                                  | 354,250                      |
| Commitments and contingencies (Note 5)  |  |                              |
| Stockholders' deficit   |  |                              |
| Common Stock, par value \$.0001 in 2010 and \$.001 in 2009; shares authorized - 100,000,000 shares in 2010 and 15,000,000 shares in 2009, shares issued and outstanding - 17,107,036 in 2010 and 11,930,000 in 2009 | 1,711                                    | 11,930                       |
| Preferred Stock, par value \$.0001 in 2010 and \$.001 in 2009; Series A Preferred Stock, shares authorized - none in 2010 and 2,000,000 in 2009, shares issued and outstanding - none in 2010 and 1,077,864 in 2009 |  | 1,078                        |
| Common stock subscribed   |  | 170,003                      |
| Additional paid in capital  | 4,664,552                                | 1,313,942                    |
| Issuances for promotion   | (788,958)                                |                              |
| Advances to stockholders  | (150,183)                                |                              |
| Deficit accumulated in the development stage  | (4,393,085)                              | (1,764,923)                  |
| Total stockholders' deficit   | (665,963)                                | (267,970)                    |
| Total liabilities and stockholders' deficit   | \$ 295,219                               | \$ 86,280                    |

The accompanying notes are an integral part of these financial statements.





**Table of Contents****AMPIO PHARMACEUTICALS, INC. AND SUBSIDIARIES****(A Development Stage Company)****Consolidated Statements of Operations****(unaudited)**

|   | Three Months Ended June 30, |              | Six Months Ended June 30, |              | December 31,<br>2008<br>(inception)<br>through<br>June 30, 2010 |
|---|-----------------------------|--------------|---------------------------|--------------|---|
|   | 2010                        | 2009         | 2010                      | 2009         |   |
| Expenses  |                             |              |                           |              |   |
| Research and development                                | 252,165                     | 258,725      | \$ 589,999                | \$ 258,725   | 1,660,369   |
| General and administrative                              | 891,387                     | 148,934      | 2,032,560                 | 148,934      | 2,473,695   |
| Total operating expenses                                | 1,143,552                   | 407,659      | 2,622,559                 | 407,659      | 4,134,064   |
| Other income (expense)                                  |                             |              |                           |              |   |
| Interest income   | 266                         | 252          | 578                       | 252          | 1,669   |
| Interest expense  | (3,222)                     |              | (6,181)                   |              | (7,595)   |
| Total other income (expense)                            | (2,956)                     | 252          | (5,603)                   | 252          | (5,926)   |
| Net loss  | \$ (1,146,508)              | \$ (407,407) | \$ (2,628,162)            | \$ (407,407) | \$ (4,139,990)  |
| Weighted average number of common shares<br>outstanding | 17,069,849                  | 5,575,856    | 15,456,332                | 10,022,308   |   |
| Basic and diluted net loss per common share             | \$ (0.07)                   | \$ (0.07)    | \$ (0.17)                 | \$ (0.04)    |   |

The accompanying notes are an integral part of these financial statements.

**Table of Contents****AMPIO PHARMACEUTICALS, INC. AND SUBSIDIARIES**

(A Development Stage Company)

**Consolidated Statements of Stockholders' Equity (Deficit)**

|   | Series A Preferred Stock |        | Common Stock |        | Common Stock Subscribed | Additional Paid in Capital |    | Receivable from Stockholders | Deficit Accumulated During the Development Stage | Total Stockholders' Equity (Deficit) |
|---|--------------------------|--------|--------------|--------|-------------------------|----------------------------|----|------------------------------|--|--------------------------------------|
|   | Shares                   | Amount | Shares       | Amount |                         | Additional Issuances       |    |                              |  |                                      |
| Balance - December 18, 2008 (date of inception)   |                          | \$     |              | \$     | \$                      | \$                         | \$ | \$                           | \$   | \$                                   |
| Issuance of common stock to founder in December, 2008   |                          |        | 1,080,000    | 1,080  |                         |                            |    |                              |  | 1,080                                |
| Net loss  |                          |        |              |        |                         |                            |    |                              | (1,080)  | (1,080)                              |
| Balance - December 31, 2008   |                          |        | 1,080,000    | 1,080  |                         |                            |    |                              | (1,080)  |                                      |
| Issuance of common stock and assumption of liabilities in asset acquisition                       |                          |        | 3,500,000    | 3,500  |                         |                            |    |                              | (252,015)  | (248,515)                            |
| Issuance of Series A Preferred Stock in exchange for cancellation of a note payable in April 2009 | 163,934                  | 164    |              |        |                         | 199,836                    |    |                              |  | 200,000                              |
| Issuance of restricted common stock in exchange for cash in April 2009                            |                          |        | 7,350,000    | 7,350  |                         |                            |    |                              |  | 7,350                                |
| Issuance of Series A Preferred Stock in exchange for cash in April and May 2009                   | 913,930                  | 914    |              |        |                         | 1,114,106                  |    |                              |  | 1,115,020                            |
| Common stock subscribed in November and December 2009   |                          |        |              |        | 170,003                 |                            |    |                              |  | 170,003                              |
| Net loss  |                          |        |              |        |                         |                            |    |                              | (1,511,828)                                      | (1,511,828)                          |
|   | 1,077,864                | 1,078  | 11,930,000   | 11,930 | 170,003                 | 1,313,942                  |    |                              | (1,764,923)                                      | (267,970)                            |

Edgar Filing: Ampio Pharmaceuticals, Inc. - Form 10-Q

|  |             |         |            |          |           |           |             |              |              |                |              |
|--|-------------|---------|------------|----------|-----------|-----------|-------------|--------------|--------------|----------------|--------------|
| Balance - December 31, 2009  |             |         |            |          |           |           |             |              |              |                |              |
| Conversion of equity in reverse merger acquisition (unaudited)   | (1,077,864) | (1,078) | 3,068,958  | (10,430) |           | 11,691    |             |              | 183          |                |              |
| Common stock subscribed in March 2010 (unaudited)  |             |         |            |          | 7,000     |           |             |              | 7,000        |                |              |
| Issuance of common stock in exchange for cash in March and June 2010, net of offering costs of \$350,000 (unaudited) |             |         | 1,078,078  | 108      | (177,003) | 1,536,522 |             |              | 1,359,627    |                |              |
| Issuance of common stock for services (unaudited)  |             |         | 1,030,000  | 103      |           | 1,802,397 | (788,958)   |              | 1,013,542    |                |              |
| Loans to shareholders (unaudited)  |             |         |            |          |           |           | (150,183)   |              | (150,183)    |                |              |
| Net loss (unaudited)   |             |         |            |          |           |           | (2,628,162) |              | (2,628,162)  |                |              |
| Balance - June 30, 2010 (unaudited)  | \$          |         | 17,107,036 | \$       | 1,711     | \$        | 4,664,552   | \$ (788,958) | \$ (150,183) | \$ (4,393,085) | \$ (665,963) |

The accompanying notes are an integral part of these financial statements.

**Table of Contents****AMPIO PHARMACEUTICALS, INC. AND SUBSIDIARIES****(A Development Stage Company)****Consolidated Statements of Cash Flows****(unaudited)**

|  | Six Months<br>Ended June 30,<br>2010 | Six Months<br>Ended June 30,<br>2009 | December 18, 2008<br>(inception) through<br>June 30, 2010 |
|--|--------------------------------------|--------------------------------------|---|
| <b>Cash flows from operating activities:</b>                                   |                                      |                                      |   |
| Net loss   | \$ (2,628,162)                       | \$ (407,407)                         | \$ (4,139,990)  |
| Common stock issued for services   | 1,013,542                            |                                      | 1,013,542   |
| <b>Adjustments to reconcile net loss to cash used in operating activities:</b> |                                      |                                      |   |
| (Increase) in prepaid expenses   | (42,487)                             | (10,002)                             | (49,523)  |
| (Increase) decrease in related party receivable                                | 23                                   | (8,445)                              | (7,238)   |
| Increase in accounts payable   | 277,789                              | (11,343)                             | 357,234   |
| Increase in accrued salaries   | 122,962                              |                                      | 196,353   |
| Increase in accrued interest payable   | 6,181                                |                                      | 7,595   |
| <b>Net cash used in operating activities</b>                                   | <b>(1,250,152)</b>                   | <b>(437,197)</b>                     | <b>(2,622,027)</b>  |
| <b>Cash flow used in investing activities</b>                                  |                                      |                                      |   |
| Purchase of fixed assets   | (2,423)                              |                                      | (2,423)   |
| <b>Net cash used in investing activities</b>                                   | <b>(2,423)</b>                       |                                      | <b>(2,423)</b>  |
| <b>Cash used in financing activities:</b>                                      |                                      |                                      |   |
| Proceeds from related party notes payable                                      | 200,000                              |                                      | 400,000   |
| Proceeds from sale of common stock   | 1,359,627                            | 7,125                                | 1,366,977   |
| Proceeds from common stock subscribed  | 7,000                                |                                      | 177,003   |
| Proceeds from sales of series A preferred stock                                |                                      | 1,115,020                            | 1,115,020   |
| Advances made to shareholders  | (150,183)                            |                                      | (150,183)   |
| Payment of liabilities assumed in asset purchase                               |                                      | (48,515)                             | (48,515)  |
| Transfer of funds into escrow  | (125,000)                            |                                      | (125,000)   |
| Release of funds from escrow   | 20,000                               |                                      | 20,000  |
| Increase in cash from acquisition  | 183                                  |                                      | 183   |
| <b>Net cash provided by financing activities</b>                               | <b>1,311,627</b>                     | <b>1,073,630</b>                     | <b>2,755,485</b>  |
| <b>Net change in cash and cash equivalents</b>                                 | <b>59,052</b>                        | <b>636,433</b>                       | <b>131,035</b>  |
| Cash and cash equivalents at beginning of period                               | 71,983                               |                                      |   |
| <b>Cash and cash equivalents at end of period</b>                              | <b>\$ 131,035</b>                    | <b>\$ 636,433</b>                    | <b>\$ 131,035</b>   |
| <b>Supplementary cash flow information:</b>                                    |                                      |                                      |   |
| Interest paid  | \$                                   | \$                                   | \$  |
| Income taxes paid  | \$                                   | \$                                   | \$  |
| <b>Non cash transactions:</b>  |                                      |                                      |   |
| Note payable assumed in asset purchase, recorded as a distribution             | \$                                   | \$ 200,000                           | \$ 200,000  |
| Accounts payable assumed in asset purchase, recorded as a distribution         | \$                                   | \$ 48,515                            | \$ 48,515   |
| Conversion of notes payable to Series A preferred stock                        | \$                                   | \$ 200,000                           | \$ 200,000  |

Edgar Filing: Ampio Pharmaceuticals, Inc. - Form 10-Q

|   |              |    |              |
|---|--------------|----|--------------|
| Common stock issued for common stock subscriptions received               | \$ 177,003   | \$ | \$ 177,003   |
| Deferred charge recorded for common stock issued in exchange for services | \$ 1,802,500 | \$ | \$ 1,802,500 |

The accompanying notes are an integral part of these financial statements.

---

**Table of Contents**

**AMPIO PHARMACEUTICALS, INC. AND SUBSIDIARIES**

**(A Development Stage Company)**

**Notes to Consolidated Financial Statements**

**(unaudited)**

**Note 1 Basis of Presentation and Merger**

These financial statements represent the consolidated financial statements of Ampio Pharmaceuticals, Inc. (Ampio), formerly known as Chay Enterprises, Inc. (Chay), and its wholly owned subsidiaries, DMI Life Sciences, Inc. (DMI) and DMI Acquisition Corp.

On March 2, 2010, DMI merged with Chay Acquisitions, a wholly-owned subsidiary of Chay Enterprises, Inc., a public company (the Merger). Chay issued 15,068,942 shares of common stock to acquire DMI, which resulted in the stockholders of DMI owning approximately 95.7% of Chay's outstanding common stock after the consummation of the Merger and before taking into account the issuance of 1,325,000 additional shares of common stock as described in Footnote 8 - Related Party Transactions. In conjunction with the Merger, Chay purchased 263,624 shares of its common stock from the Chay Control Shareholders for \$150,000 in cash.

As a result of the Merger, DMI became a wholly owned subsidiary of Chay. For accounting purposes, the merger was treated as a reverse acquisition with DMI as the acquirer and Chay as the acquired party. As a result, the business and financial information included in the report is the business and financial information of DMI. The accumulated deficit of Chay has been included in additional paid in capital. Pro-forma information has not been presented as the financial information of Chay was insignificant.

Subsequent to the Merger, Chay Enterprises, Inc. was renamed Ampio Pharmaceuticals, Inc.

The preparation of our consolidated financial statements and related disclosures in conformity with generally accepted accounting principles in the United States (GAAP) requires us to make estimates and judgments that affect the amounts reported in our financial statements and accompanying notes. The statements reflect all normal recurring adjustments, which, in the opinion of the Ampio's management, are necessary for the fair presentation of financial position, results of operations and cash flows for the periods presented.

The accompanying financial statements should be read in conjunction with DMI Life Sciences, Inc.'s consolidated financial statements for the years ended December 31, 2009 and 2008 filed with Ampio's Form 8-K dated March 2, 2010, which includes all disclosures required by GAAP. The results of operations for the periods ended June 30, 2010 and 2009 are not necessarily indicative of expected operating results for the full year.

**Note 2 Restricted Cash**

Restricted cash of \$105,000 represents cash placed in escrow pursuant to the Put Agreement described in Footnote 5 - Commitments and Contingencies.

**Note 3 Related Party Notes Payable**

As of June 30, 2010, Ampio had \$100,000 in notes payable to DMI's founder and \$300,000 payable to DMI BioSciences, Inc., a stockholder. The related party notes payable are unsecured, bear interest at 6% and mature on September 2, 2010. The Company accrued interest on these notes of \$3,222 and \$0 in the second quarters of 2010 and 2009 and \$6,181 and \$0 in the six months ended June 30, 2010 and 2009, respectively.

**Note 4 Income Taxes**

As of June 30, 2010, Ampio provided a full valuation allowance against the deferred tax asset based on the weight of available evidence, both positive and negative, including the Ampio's operating loss, which indicated that it is more likely than not that such benefits will not be realized.

**Note 5 Commitments and Contingencies**

## Edgar Filing: Ampio Pharmaceuticals, Inc. - Form 10-Q

As condition of the Merger, Ampio and certain of its stockholders (the Guarantors) and the Chay Control Shareholders entered into a Securities Put and Guarantee Agreement, or the Put Agreement. The Put Agreement provides that if Ampio is not successful in obtaining a minimum of \$5.0 million in financing, within 150 days after the closing of the Merger, the Chay Control Shareholders will have the right to put back to Ampio all of the Chay common stock then owned by the Chay Control Shareholders for a put price of \$250,000, subject to adjustment. Under the Put Agreement, the Guarantors agreed to jointly guarantee the payment of the put price by Ampio if the put right becomes exercisable in accordance with its terms. In addition, Ampio placed into escrow a cash deposit of \$125,000 that will be paid to the Chay Control Shareholders in the event the put right becomes exercisable by its terms. If paid to the Chay Control Shareholders in accordance with the escrow agreement, such payment will reduce the amount the Guarantors would be required to pay on exercise of the put right by the Chay Control Shareholders. The Chay Control Shareholders released to Ampio \$20,000 of the funds in escrow in June 2010 and \$75,000 in July 2010. The Chay Control Shareholders have not exercised their put right.

## **Table of Contents**

### **Note 6 Common Stock**

#### ***Capital Stock***

Prior to the Merger, DMI had 15,000,000 shares of common stock with a par value of \$0.001 and 2,000,000 share of Series A Preferred Stock authorized with a par value of \$0.001. At June 30, 2010, Ampio had 100,000,000 shares of common stock authorized with a par value of \$0.0001 per share, and 10,000,000 shares of preferred stock authorized with a par value of \$0.0001 per share.

#### ***Capital Transactions***

As set forth in Footnote 1 Basis of Presentation and Merger, DMI and Chay completed a reverse merger in March 2010. In conjunction with the Merger, DMI's Series A Preferred Stock was automatically converted into common stock. As result of the Merger, related stock transactions and the conversion of Series A Preferred Stock, Ampio common stock outstanding increased by 3,068,958 shares.

Ampio issued 1,031,078 shares of common stock in March 2010 for \$1,454,380 in cash (net of \$350,000 in offering costs), of which \$170,003 had been received in 2009 and previously classified as common stock subscribed.

Ampio issued 1,030,000 shares of common stock in January, February and March 2010 in exchange for services. The shares were recorded at their fair value, \$1.75 per share or \$1,802,500. Ampio recorded \$363,125 and \$1,013,542 as expense in the three and six months ended June 30, 2010, respectively see Note 7. The remaining \$788,958 is reflected as a deferred charge in stockholders' equity, and will be recognized into expense as the services are provided.

Ampio issued 47,000 shares of Common Stock in April 2010 for \$82,250 in cash, of which \$7,000 had been received in March 2010 and was previously classified as common stock subscribed.

#### ***Equity Incentive Plan***

Ampio adopted a stock plan in March 2010. The stock plan reserves up to 2,500,000 shares of common stock for issuance to officers, directors, employees and consultants through various means, including incentive stock options, non-qualified stock options, restricted stock grants, and other forms of equity equivalents. As of August 12, 2010, Ampio had issued options with respect to all 2,500,000 shares reserved under the plan.

### **Note 7 Stock-Based Compensation**

Stock based compensation related to common stock issued to third party vendors in exchange for services of \$363,125 and \$1,013,542 in the three and six months ended June 30, 2010, respectively, was included in general and administrative expenses in the statement of operations. The common stock was recorded at its fair value at the dates Ampio became obligated to issue the shares, and is recognized as expense as the services are provided.

### **Note 8 Related Party Transactions**

Immediately prior to the Merger, Chay accepted subscriptions for an aggregate of 1,325,000 shares of common stock from six officers and employees of DMI, for a purchase price of \$150,183. DMI made advances to the six officers and employees in the aggregate amount of \$150,183 to facilitate the share purchases by the six purchasers. These shares were issued immediately before the closing of the Merger. The advances are non-interest bearing and due on demand and are classified as a reduction to stockholders' equity.

Related party receivable at June 30, 2010 consisted of \$1,527 receivable from DMI Bio Sciences, Inc. and \$5,711 from the Chay Control Shareholders.

### **Note 9 Subsequent Events**

During August 2010, Ampio issued \$430,000 in principal amount of 8% Senior Convertible Unsecured Debentures due January 31, 2011 (the Debentures) together with warrants to related parties.

The Debentures are convertible into the Ampio's common stock at the lower of \$1.75 per share, or the per-share price at which the Company issues common stock in an underwritten offering of \$10,000,000 (the Offering). The Debentures are due and payable at the earlier of one



## Edgar Filing: Ampio Pharmaceuticals, Inc. - Form 10-Q

business day after the closing of the Offering or January 31, 2011. The Debenture terms specify that Ampio is obligated to obtain an extension of the \$400,000 in principal amount of promissory notes previously issued to DMI BioSciences, Inc., to a due date consistent with the maturity date of the Debentures, and require Ampio to obtain a subordination agreement from DMI BioSciences, Inc., such that the Debentures will jointly constitute the senior unsecured indebtedness of Ampio.

**Table of Contents**

In conjunction with the issuance of the Debentures, the Company issued Warrants to the purchasers of the Debentures giving them the right to purchase an aggregate of 21,500 shares of the Company's common stock at an exercise price equal to the price at which the Company sells common stock in the Offering.

During August 2010, Ampio issued options to purchase 2,500,000 shares of common stock to its officers, directors and general counsel. The stock options have an exercise price of \$1.01 per share and have a term of ten years.

During August 2010, Ampio entered into employment agreements with one of its officers. Ampio expects to enter into employment agreements with two additional officers on or about August 18, 2010. Under the employment agreements, the officers are collectively entitled to receive \$415,000 in annual salaries. Upon completion of a financing of \$10,000,000 or more, the annual salaries will collectively increase to \$780,000. The employment agreements have terms of three years.

---

**Table of Contents**

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.**  
**MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF**

**OPERATIONS**

*This discussion should be read in conjunction with Ampio Pharmaceutical Inc.'s historical financial statements filed with this report. The following discussion and analysis contain forward-looking statements that involve risks and uncertainties. Actual results could differ materially from those projected in the forward-looking statements. For additional information regarding these risks and uncertainties, please see Part II, Item 1A of this Form 10-Q, Risk Factors, and the risk factors included in Ampio's Current Report on Form 8-K filed with the Securities and Exchange Commission on March 8, 2010.*

***Overview***

Ampio Pharmaceuticals, Inc. was created through the March 2010 merger (the Merger) of DMI Life Sciences, Inc., a Delaware corporation (DMI) with Chay Acquisitions, Inc., a wholly-owned subsidiary of Chay Enterprises, Inc. (Chay). As a result of the Merger, DMI became a wholly owned subsidiary of Chay. For accounting purposes, the merger was treated as a reverse acquisition with DMI as the acquirer and Chay as the acquired party. As a result, the business and financial information included in the report is the business and financial information of DMI. Subsequent to the Merger, Chay Enterprises, Inc. was renamed Ampio Pharmaceuticals, Inc., or Ampio, and reincorporated in Delaware. In this Form 10-Q, references to we, us, or similar terms mean Ampio and its subsidiaries, including DMI.

DMI was originally incorporated in Delaware in December 2008 and began conducting business in April 2009, at which time DMI purchased certain assigned intellectual property (including 107 patents and pending patent applications), business products and tangible property from DMI BioSciences, Inc., or BioSciences. Since the acquisition of the BioSciences assets, we have raised \$1,500,000 through sales of common stock, strengthened our management team, completed the reverse merger into a public entity and continued our research and development activities. In addition to our current business described in the next paragraph, in April 2010, we entered into a letter of intent to acquire BioSciences in a tax-free exchange. BioSciences' significant intellectual property asset is a drug that treats male sexual dysfunction, which we refer to as the PE drug.

We are a development stage company engaged in developing innovative, proprietary pharmaceutical drugs and diagnostic products to identify, treat and prevent a broad range of human diseases including metabolic disorders, cancer, and acute and chronic inflammation diseases. We intend to develop proprietary pharmaceutical drugs and diagnostic products which capitalize on DMI's intellectual property that includes assigned patents, pending patent applications, licensed patents, and trade secrets and know-how, some of which may be the subject of future patent applications. Our intellectual property is strategically focused on three primary areas: new uses for FDA-approved drugs, referred to as repurposed drugs, new molecular entities, or NMEs, and rapid point-of-care tests for diagnosis, monitoring and screening.

***Known Trends or Future Events***

The assets we purchased from BioSciences in April 2009 generated minimal revenues prior to their acquisition. We have not generated any revenues since the acquisition of assets from BioSciences. Since purchasing specific assets from BioSciences including patents, pending patent applications and minimal fixed assets as well as absorbing some of BioSciences' employees, we have engaged in organizational activities, conducted a private placement, added to our management team, and completed the Merger. During April 2010, we announced that we had entered into a non-binding letter of intent to acquire BioSciences.

We expect to raise substantial additional capital in the near future in order to accelerate our development activities associated with several of our leading product candidates. We cannot assure you that we will secure such financing or that it will be adequate to execute our business strategy. Even if we obtain this financing, it may be costly and may require us to agree to provisions that will favor new investors over our existing shareholders. Due to the time required to conduct clinical trials and obtain regulatory approval for any of our product candidates, we anticipate it will be some time before we generate substantial revenues, if ever, and we expect that our research and development expenses will increase significantly. We expect to generate operating losses for the foreseeable future, but intend to limit the extent of these losses by entering into co-development or collaboration agreements with one or more strategic partners. We have no such agreements in effect at the current time.

We expect our general and administrative expenses to increase substantially in 2010 as a result of our becoming a public company. Among other things, we expect expenses such as compliance and governance costs, legal and accounting fees, directors' and officers' liability insurance premiums, and directors' fees will increase significantly. We will also incur investor relations expenses, listing fees, and other costs associated with being a public company.



## **Table of Contents**

### ***Significant Accounting Policies and Estimates***

This Management's Discussion and Analysis section discusses our financial statements, which have been prepared in accordance with accounting policies generally accepted in the United States of America. The preparation of the financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments, including those related to recoverability of long-lived assets, contingencies, and litigation. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The methods, estimates, and judgments used by us in applying these most critical accounting policies have a significant impact on the results we report in our financial statements.

### ***Cash and Cash Equivalents***

We consider all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents consist primarily of money market investments. We maintain balances from time to time in excess of the federally insured limits.

### ***Patents***

Costs of establishing patents consisting of legal fees paid to third parties and related costs are currently expensed as incurred. We will continue this practice until such time as we can demonstrate that such costs add economic value to our business, in which case we will capitalize such costs as part of our intangible assets. The primary consideration in making this determination is whether or not we can demonstrate that such costs have, in fact, increased the economic value of our intellectual property. Legal and related costs which do not meet the above criteria will be expensed as incurred in accordance with our current practice.

### ***Stock-Based Compensation***

We account for share-based payments by recognizing compensation expense based upon the estimated fair value of the awards on the date of grant. We determine the estimated grant fair value using the Black-Scholes option pricing model and recognize compensation costs ratably over the vesting period using the straight-line method. Common stock issued in exchange for services is recorded at the fair value of the common stock on the date at which we becomes obligated to issue the shares. The value of the shares is expensed over the service period.

### ***Income Taxes***

Ampio uses the liability method of accounting for income taxes. Under this method, Ampio recognizes deferred assets and liabilities based on the differences between the tax basis of assets and liabilities and their reported amounts in the financial statements that will result in taxable or deductible amounts in future years. Ampio establishes a valuation allowance for all deferred tax assets for which there is uncertainty regarding realization.

### ***Research and Development***

Research and development costs are expensed as incurred.

### ***Recently Issued Accounting Pronouncements***

Ampio has reviewed the accounting pronouncements up through Update No. 2010-20 and does not expect any of them to have a material impact on its financial statements.

### ***Results of Operations***

Results of operations for the three and six months ended June 30, 2010 and 2009 are as follows:

### ***Revenue***

We are a development stage enterprise and have not generated material revenue in our operating history.



**Table of Contents****Expenses***Research and Development*

Research and development costs were \$438,000 and \$259,000 in the three months ended June 30, 2010 and 2009, and \$776,000 and 259,000 in the six months ended June 30, 2010 and 2009, respectively. Research and development costs consist of the research and development of patents and intellectual property as well as drug development and clinical trials. The increase in expenses in 2010 relates to the increase in business activity as Ampio did not begin incurring operating expenses until April 2009. We have not capitalized any of our research and development costs.

*General and Administrative*

General and administrative costs are summarized as follows:

|                             | Three Months ended June 30, |            | Six Months ended June 30, |            |
|-----------------------------|-----------------------------|------------|---------------------------|------------|
|                             | 2010                        | 2009       | 2010                      | 2009       |
| Stock-based compensation    | \$ 364,000                  | \$         | \$ 1,014,000              | \$         |
| Professional fees           | 63,000                      | 12,000     | 354,000                   | 12,000     |
| Labor                       | 187,000                     | 119,000    | 322,000                   | 119,000    |
| Occupancy, travel and other | 91,000                      | 18,000     | 157,000                   | 18,000     |
|                             | \$ 705,000                  | \$ 149,000 | \$ 1,847,000              | \$ 149,000 |

Stock-based compensation consists of the fair value of shares issued to outside consultants for services provided. Professional fees consists primarily of legal, audit and accounting costs related to the Merger and public company compliance costs. Labor consists of compensation costs attributable to Ampio's administrative employees. The increase in expenses in 2010 relates to the increase in business activity as Ampio did not begin incurring operating expenses until April 2009.

*Net Cash Used in Operating Activities*

During the six months ended June 30, 2010, our operating activities used \$1,250,000 of cash. The use of cash reflected a \$2,628,000 net loss, a non-cash charge of \$1,014,000 for stock based compensation, an increase in accounts payables of \$278,000 relating to professional fees incurred in conjunction with the Merger and other expenses, an increase in accrued salaries of \$123,000 resulting from deferral of salaries by our management team, and changes in other assets and current liabilities which provided net cash of \$36,000.

*Net Cash from Financing Activities*

Net cash provided by our financing activities was \$1,312,000 for the six months ended June 30, 2010. During this period, we received \$200,000 in loans from shareholders and \$1,367,000 from the sale and subscription of common stock. Immediately prior to the Merger, we made advances of \$150,000 to stockholders. Pursuant to the terms of the Merger Agreement, we were also required to place \$125,000 in restricted cash into an escrow account, \$20,000 of which was released in June and \$75,000 was released in July 2010. The remaining escrowed funds are to be released to us on closing of a Qualified Financing (as defined) during the escrow period, or will be released to the principal stockholders of Chay if we do not obtain such financing during the escrow period, subject to adjustment for any sales of our common stock made by the Chay principal stockholders.

*Liquidity and Capital Resources*

We had unrestricted cash of \$131,000 at June 30, 2010, and an additional \$75,000 was released from restricted cash subsequent to June 30, 2010. We raised approximately \$1,500,000 in a private placement of common stock conducted from November 2009 to March, 2010 and are actively seeking to raise additional capital. As of June 30, 2010 we had \$400,000 in notes payable to stockholders, which mature on the earlier of a minimum financing of \$5,000,000 or September 2, 2010. During August 2010, stockholders loaned us an additional \$430,000. The loans mature at the earlier of a minimum financing of \$10,000,000 or January 31, 2011. Additional loans from our stockholders may be a source of short-term liquidity. However, there is currently no formal commitment from our stockholders to provide additional short-term financing. In

order to execute on our business plan, it will be necessary for us to raise additional capital.

***Off Balance Sheet Arrangements***

We do not have off-balance sheet arrangements, financings, or other relationships with unconsolidated entities or other persons, also known as variable interest entities.



## **Table of Contents**

### ***Contractual Obligations***

As condition of the Merger, Ampio and certain of its shareholders (the Guarantors) and the Chay Control Shareholders entered into a Securities Put and Guarantee Agreement, or the Put Agreement. The Put Agreement provides that if Ampio is not successful in obtaining a minimum of \$5.0 million in financing, within 150 days after the closing of the Merger, the Chay Control Shareholders will have the right to put back to Ampio all of the Chay common stock then owned by the Chay Control Shareholders for a put price of \$250,000, subject to adjustment. Under the Put Agreement, the Guarantors agreed to jointly guarantee the payment of the put price by DMI if the put right becomes exercisable in accordance with its terms. In addition, Ampio placed into escrow a cash deposit of \$125,000 that will be paid to the Chay Control Shareholders in the event the put right becomes exercisable by its terms. The Chay Control Shareholders have since released \$95,000 of the funds in escrow. If any amounts are paid to the Chay Control Shareholders in accordance with the escrow agreement, such payment will reduce the amount the Guarantors would be required to pay on exercise of the put right.

### **Item 3. Quantitative and Qualitative Disclosures About Market Risk.**

The Company is not currently exposed to material market risk arising from financial instruments, changes in interest rates or commodity prices, or fluctuations in foreign currencies. The Company has no need to hedge against any of the foregoing risks and therefore currently engages in no hedging activities. Our outstanding indebtedness is limited currently to fixed rate instruments.

### **Item 4T. Controls and Procedures.**

As of the end of the period covered by this Quarterly Report on Form 10-Q, an evaluation was carried out by the Company's management, with the participation of the Chief Executive Officer and Chief Financial Officer, of the effectiveness of the Company's disclosure controls and procedures, as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934. Based on such evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company's disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports the Company files or furnishes under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and regulations, and are operating in an effective manner.

The Company made no significant changes in its internal controls over financial reporting or in other factors that materially affected, or are reasonably likely to materially affect, these controls during the six months ended June 30, 2010.

**Table of Contents**

**PART II. OTHER INFORMATION**

**Item 1. Legal Proceedings.**

The Company is currently not party to any material pending legal proceedings, whether routine or non-routine.

**Item 1A. Risk Factors.**

Certain factors exist which may affect the Company's business and could cause actual results to differ materially from those expressed in any forward-looking statements. The Company has not experienced any material changes from those risk factors as previously disclosed in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on March 8, 2010 (the "Form 8-K"). However, the Company continues to require additional capital, the receipt of which is not assured.

**Item 2. Unregistered Sales of Securities and Use of Proceeds.**

The Company previously furnished the information required by Item 701 of Regulation S-K in the Form 8-K. The Company incorporates by reference herein the information included in Item 3.02 of the Form 8-K.

The Company issued 47,000 shares of stock in June 2010. The Company did not provide the information required by Item 701 of Regulation S-K on Form 8-K for reasons of materiality.

**Item 3. Defaults Upon Senior Securities.**

None.

**Item 4. [Removed and Reserved].**

**Item 5. Other Information.**

On April 22, 2010, the Company issued a press release announcing the execution of a letter of intent under which the Company intends to acquire DMI BioSciences, Inc. On April 27, 2010, a report of current event was filed with respect to the letter of intent.

On July 21 and 27, we issued two press releases, the first of which concerned the initiation of a Phase II clinical trial for one of our product candidates, and the second of which concerned the finalization of negotiations concerning the terms of a definitive agreement to acquire DMI BioSciences, Inc. The July 27 press release contained an error in the title of the release which was corrected in a press release issued on August 3, 2010.

**Item 6. Exhibits**

| <b>Exhibit Number</b> | <b>Description</b>  |
|-----------------------|---|
| 10.1                  | Notes Payable dated June 23, 2010, by and between DMI BioSciences, Inc. and Ampio Pharmaceuticals, Inc. |
| 31.1                  | Certificate of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.       |

## Edgar Filing: Ampio Pharmaceuticals, Inc. - Form 10-Q

- 31.2 Certificate of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
- 32.1 Certificate of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
- 99.1 Press release by Ampio Pharmaceuticals, Inc. dated July 21, 2010.
- 99.2 Press release by Ampio Pharmaceuticals, Inc. dated July 21, 2010.
- 99.3 Correction to press release by Ampio Pharmaceuticals, Inc. dated August 3, 2010.

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

AMPIO PHARMACEUTICALS, INC.

By: /s/ DONALD B. WINGERTER, JR.  
**Donald B. Wingerter, Jr.**

**Chief Executive Officer**

**Date: August 16, 2010**

By: /s/ BRUCE G. MILLER  
**Bruce G. Miller**

**Chief Financial Officer**

**Date: August 16, 2010**